Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $48.85 Average PT from Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN) has earned a consensus rating of “Buy” from the fifteen research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $47.46.

Several analysts have issued reports on the stock. Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Robert W. Baird began coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 price target on the stock. JPMorgan Chase & Co. cut their price objective on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday. Royal Bank of Canada restated an “outperform” rating and set a $45.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Finally, BMO Capital Markets began coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 price target on the stock.

Insiders Place Their Bets

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the transaction, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 6,237 shares of company stock valued at $77,760 over the last 90 days. 20.77% of the stock is owned by company insiders.

Institutional Trading of Dyne Therapeutics

Several hedge funds have recently made changes to their positions in the stock. FMR LLC increased its position in Dyne Therapeutics by 69.7% in the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after buying an additional 3,707,734 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Dyne Therapeutics by 8.3% in the 4th quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company’s stock worth $173,808,000 after acquiring an additional 566,146 shares during the period. RTW Investments LP lifted its position in Dyne Therapeutics by 6.8% in the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock valued at $244,926,000 after purchasing an additional 431,503 shares during the last quarter. RA Capital Management L.P. boosted its stake in Dyne Therapeutics by 5.5% during the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after purchasing an additional 331,940 shares during the period. Finally, State Street Corp grew its position in Dyne Therapeutics by 13.8% in the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company’s stock worth $130,816,000 after purchasing an additional 440,890 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Trading Down 1.5 %

Shares of NASDAQ DYN opened at $12.08 on Friday. The stock has a fifty day moving average price of $13.60 and a 200 day moving average price of $24.26. Dyne Therapeutics has a 12-month low of $11.18 and a 12-month high of $47.45. The company has a market cap of $1.37 billion, a P/E ratio of -3.39 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. On average, sell-side analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.